Thompson Siegel & Walmsley LLC Sells 15,347 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

Thompson Siegel & Walmsley LLC lowered its position in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 5.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 252,455 shares of the company’s stock after selling 15,347 shares during the quarter. Thompson Siegel & Walmsley LLC owned 0.38% of QuidelOrtho worth $11,512,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of QDEL. Vanguard Group Inc. lifted its holdings in shares of QuidelOrtho by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 4,879,143 shares of the company’s stock valued at $233,906,000 after acquiring an additional 37,733 shares during the last quarter. Gamco Investors INC. ET AL grew its stake in QuidelOrtho by 3.5% in the 1st quarter. Gamco Investors INC. ET AL now owns 207,801 shares of the company’s stock worth $9,962,000 after acquiring an additional 7,121 shares in the last quarter. Gabelli Funds LLC increased its position in shares of QuidelOrtho by 7.1% during the first quarter. Gabelli Funds LLC now owns 144,130 shares of the company’s stock worth $6,910,000 after acquiring an additional 9,500 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of QuidelOrtho by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,854 shares of the company’s stock valued at $1,911,000 after acquiring an additional 1,648 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its stake in QuidelOrtho by 15.9% in the first quarter. Silvercrest Asset Management Group LLC now owns 216,349 shares of the company’s stock worth $10,372,000 after purchasing an additional 29,721 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Insider Activity at QuidelOrtho

In other QuidelOrtho news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $35.31, for a total transaction of $291,667,061.73. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.00% of the stock is owned by insiders.

QuidelOrtho Trading Up 1.1 %

Shares of QDEL stock opened at $37.89 on Friday. The stock has a market cap of $2.55 billion, a P/E ratio of -1.34 and a beta of 0.12. The company has a quick ratio of 0.81, a current ratio of 1.38 and a debt-to-equity ratio of 0.68. The business has a fifty day simple moving average of $41.62 and a 200-day simple moving average of $40.37. QuidelOrtho Co. has a fifty-two week low of $29.74 and a fifty-two week high of $75.86.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.55. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. The firm had revenue of $727.00 million during the quarter, compared to the consensus estimate of $642.16 million. During the same quarter in the previous year, the business earned $0.90 earnings per share. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, analysts forecast that QuidelOrtho Co. will post 1.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. William Blair reiterated a “market perform” rating on shares of QuidelOrtho in a report on Wednesday. Craig Hallum raised shares of QuidelOrtho from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $40.00 to $57.00 in a research report on Thursday, September 5th. UBS Group began coverage on shares of QuidelOrtho in a research note on Thursday, September 19th. They issued a “neutral” rating and a $50.00 target price for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target on shares of QuidelOrtho in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $58.83.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.